Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Current Assets (2016 - 2025)

Historic Current Assets for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $7.2 million.

  • Northwest Biotherapeutics' Current Assets rose 3863.64% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 3863.64%. This contributed to the annual value of $4.1 million for FY2024, which is 152.73% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Current Assets of $7.2 million as of Q3 2025, which was up 3863.64% from $6.2 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Current Assets high stood at $17.3 million for Q4 2021, and its period low was $4.1 million during Q4 2024.
  • In the last 5 years, Northwest Biotherapeutics' Current Assets had a median value of $7.2 million in 2022 and averaged $7.7 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Current Assets soared by 26632.48% in 2021, and later tumbled by 5623.34% in 2023.
  • Northwest Biotherapeutics' Current Assets (Quarter) stood at $17.3 million in 2021, then crashed by 45.49% to $9.4 million in 2022, then tumbled by 56.23% to $4.1 million in 2023, then dropped by 1.53% to $4.1 million in 2024, then surged by 77.2% to $7.2 million in 2025.
  • Its Current Assets stands at $7.2 million for Q3 2025, versus $6.2 million for Q2 2025 and $4.7 million for Q1 2025.